| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
2 companies
Davis Blaine serves as a Chief Financial Officer at RNAC and has filed Form 4s across 2 companies. Across recent SEC filings that breaks down to 1 buy and 3 sells. Those positions are worth an estimated $891K at current prices.
Historically, Davis Blaine's trades have earned a strong insider score of 75/100 across 3 rated trades. Over a 12-month horizon, 100.0% of those trades were profitable, with an average 12-month return of +60.0%.
The biggest single holding is RNAC (~$827K) as Chief Financial Officer. The recent filings there lean toward selling, a net 18,580 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 6, 2026 | RNAC Cartesian Therapeutics, Inc. | Chief Financial Officer | Sell | 10,591 | $6.82 | $72,227.44 | -8.0% | -11.4% | - | |
| Jan 6, 2025 | RNAC Cartesian Therapeutics, Inc. | Chief Financial Officer | Sell | 7,989 | $16.78 | $134,035.55 | -7.8% | -42.7% | -60.1% | |
| Sep 22, 2020 | TARA Protara Therapeutics, Inc. | Chief Financial Officer | Buy | 1,481 | $16.91 | $25,037.79 | New | - | - |